SAB Biotherapeutics annual return on equity
2021
2022
2023
2024
2025
SAB Biotherapeutics Return on Equity (ROE) Growth & History (SABS)
SAB Biotherapeutics's return on equity was 14.96% for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 14.96% | +96.88 pp |
| 2024 | 2024-12-31 | −81.92% | +13.59 pp |
| 2023 | 2023-12-31 | −95.51% | −41.66 pp |
| 2022 | 2022-12-31 | −53.85% | +35.06 pp |
| 2021 | 2021-12-31 | −88.91% | — |
SAB Biotherapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −10.18% | +50.34 pp |
| Q1 2026 | 2026-03-31 | −9.96% | +11.97 pp |
| Q4 2025 | 2025-12-31 | −10.65% | +25.59 pp |
| Q3 2025 | 2025-09-30 | 51.32% | +76.26 pp |
| Q2 2025 | 2025-06-30 | −60.52% | −45.69 pp |
| Q1 2025 | 2025-03-31 | −21.94% | −12.81 pp |
| Q4 2024 | 2024-12-31 | −36.25% | +26.76 pp |
| Q3 2024 | 2024-09-30 | −24.93% | +4.25 pp |
| Q2 2024 | 2024-06-30 | −14.83% | +16.36 pp |
| Q1 2024 | 2024-03-31 | −9.13% | +17.39 pp |
| Q4 2023 | 2023-12-31 | −63.01% | −37.47 pp |
| Q3 2023 | 2023-09-30 | −29.18% | −8.29 pp |
| Q2 2023 | 2023-06-30 | −31.19% | −19.01 pp |
| Q1 2023 | 2023-03-31 | −26.52% | −28.99 pp |
| Q4 2022 | 2022-12-31 | −25.53% | +5.84 pp |
| Q3 2022 | 2022-09-30 | −20.89% | −9.81 pp |
| Q2 2022 | 2022-06-30 | −12.19% | −4.74 pp |
| Q1 2022 | 2022-03-31 | 2.47% | −4.44 pp |
| Q4 2021 | 2021-12-31 | −31.38% | — |
| Q3 2021 | 2021-09-30 | −11.08% | — |
| Q2 2021 | 2021-06-30 | −7.44% | — |
| Q1 2021 | 2021-03-31 | 6.91% | — |
SAB Biotherapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, SAB Biotherapeutics's return on equity increased from −88.91% to 14.96%, a change of +103.87 percentage points. The latest reported quarter, Q2 2026, shows −10.18%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗